Trusted Resources: Evidence & Education
Scientific literature and patient education texts
The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy
source: European Thyroid Journal
year: 2016
authors: Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM
summary/abstract:Graves’ orbitopathy (GO) is the main extrathyroidal manifestation of Graves’ disease, though severe forms are rare. Management of GO is often suboptimal, largely because available treatments do not target pathogenic mechanisms of the disease. Treatment should rely on a thorough assessment of the activity and severity of GO and its impact on the patient’s quality of life. Local measures (artificial tears, ointments and dark glasses) and control of risk factors for progression (smoking and thyroid dysfunction) are recommended for all patients.
In mild GO, a watchful strategy is usually sufficient, but a 6-month course of selenium supplementation is effective in improving mild manifestations and preventing progression to more severe forms. High-dose glucocorticoids (GCs), preferably via the intravenous route, are the first line of treatment for moderate-to-severe and active GO. The optimal cumulative dose appears to be 4.5-5 g of methylprednisolone, but higher doses (up to 8 g) can be used for more severe forms.
Shared decision-making is recommended for selecting second-line treatments, including a second course of intravenous GCs, oral GCs combined with orbital radiotherapy or cyclosporine, rituximab or watchful waiting. Rehabilitative treatment (orbital decompression surgery, squint surgery or eyelid surgery) is needed in the majority of patients when GO has been conservatively managed and inactivated by immunosuppressive treatment.
organization: University of Insubria, Italy; Catholic University of Louvain, Belgium; Aristotle University of Thessaloniki, Greece; Universitätsklinikum Essen, Germany; Johannes Gutenberg University Medical Center, Germany; University of Pisa, Italy; Newcastle upon Tyne Hospitals NHS Foundation Trust, UK; University of Milan, Italy; University of Amsterdam, NetherlandsDOI: 10.1159/000443828
read more
Related Content
-
Radioiodine Ablation of Postsurgical Thyroid Remnants After Treatment With Recombinant Human TSH (rhTSH) in Patients...Context: Recent evidence suggests thyro...
-
Patients’ Perceptions and Views of Surgery and Radioiodine Ablation in the Definitive Management of GravesR...Background: Patients' perceptions and p...
-
Comparison of Endoscopic and Conventional Open Thyroidectomy for Graves’ Disease: A Meta-analysisBackground: Despite experience with the...
-
“TED Today” Episode 1https://www.facebook.com/ThyroidEyes/vid...
-
Eric Hink, MDEric Hink is Associate Professor of opht...
-
Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presen...Horizon Therapeutics plc today announced...
-
Therapy of Endocrine Disease: Endocrine Dilemma: Management of Graves’ OrbitopathyManagement of Graves' orbitopathy (GO) m...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.